Generic Name Pharmacologic Long-acting synthetic Dexamethasone is a Contraindications: CNS: euphoria, BEFORE

Dexamethasone Acetate Class: adrenocorticoid with synthetic glucocorticoid Systemic fungal infections; insomnia, psychotic -Read ticket, compare with
Glucocorticoid intense antiinflammatory which decreases Hypersensitivity to any component of behavior, pseudotumor doctor’s order and have
Trade Name (glucocorticoid) activity inflammation by the product, including sulfites. cerebri, vertigo, signed by head nurse.
Dexameth, Dexasone, Therapeutic Class: and minimal inhibiting the migration Dexamethasone sodium phosphate - Tell patient not to stop
headache, paresthesia,
Dexone Anti-inflammatory; mineralocorticoid activity. of leukocytes and reversal contains sodium bisulfite, a sulfite that drug abruptly or without
Immunosuppressant Antiinflammatory action: of increased capillary may cause allergic-type reactions,
seizures. prescriber’s consent
Patient's Dose Prevents accumulation of permeability. It including anaphylactic symptoms and - Warn patient on long term
5mg IVTT BID inflammatory cells at sites suppresses normal life-threatening or less severe asthmatic CV: heart failure, therapy about cushingoid
of infection; inhibits immune response. episodes in certain susceptible people. hypertension, edema, effects (moon face, buffalo
Maximum Dose phagocytosis, lysosomal arrhythmias, hump.)
16mg/mL TID enzyme release, and Patient's Indication: Precautions: thrombophlebitis, - Determine whether patient
synthesis of selected for inflammatory actions Psychotic derangements may appear thromboembolism. is sensitive to other
Minimum Dose chemical mediators of and neoplasia. Following prolonged therapy, corticosteroids
8mg/mL TID inflammation; reduces withdrawal symptoms may include EENT: cataracts, -Take baseline vital signs.
capillary dilation and fever, myalgia, arthralgia, and malaise. glaucoma. (TPRBP, Pain score if
Availability permeability. Use lowest possible dose applicable)
8 mg/mL, 16 mg/mL Immunosuppression: Not
injection suspension; clearly understood, but may Drug Interactions: GI: peptic ulceration, GI DURING
be due to prevention or Drug: BARBITURATES, phenytoin, irritation, increased -Greet pt. and SO, verify
Route suppression of delayed rifampin increase steroid metabolism— appetite, pancreatitis, client identity (verbal, pt.
IV hypersensitivity immune dosage of dexamethasone may need to nausea, vomiting. tags, bed number). Assess
reaction. be increased; amphotericin B, baseline v/s.
DIURETICS compound potassium loss; GU: menstrual -Provide comfort measures.
ambenonium, neostigmine, irregularities. -Monitor for exacerbation of
Therapeutic Effect pyridostigmine may cause severe muscle seizure activity.
Drug has antiinflammatory weakness in patients with myasthenia Metabolic: -Monitor for therapeutic
and immunosuppression gravis; may inhibit antibody response to effectiveness
hypokalemia,
properties. VACCINES, TOXOIDS.
hypocalcemia, AFTER
Pharmacokinetics: hyperglycemia, -Advise patient NOT to
Absorption: Readily carbohydrate intolerance, drink alcohol while are
absorbed from GI tract. increased urine glucose using haloperidol.
Onset: Rapid onset. and calcium levels. -Monitor patient weight,
Peak: 1–2 h PO; 8 h IM. blood pressure, and
Duration: 2.75 d PO; 6 d Musculoskeletal: electrolyte levels.
IM; 1–3 wk intralesional, muscle weakness, - Monitor patient for
intraarticular. osteoporosis, growth cushingoid effects,including
Distribution: Crosses suppression in children. moonface, buffalo hump,
placenta; distributed into thinning of hair.
breast milk. -Drink adequate fluids.
Elimination: Skin: hirsutism, delayed -Warn patient about easy
Hypothalamus-pituitary wound healing, acne, bruising
skin eruptions, atrophy
\
 axis suppression: 36–54 h. at I.M. injection sites.
Half-Life: 3–4.5 h.
Other: susceptibility to
infections, acute adrenal
insufficiency following
increased stress
(infection, surgery, or
trauma) or abrupt
withdrawal after long-
term therapy, cushingoid
state (moonface, buffalo
hump, central obesity),
growth suppression in
children, increased
sweating, hirsutism.

Doenges,M.E,Moorhouse Doenges,M.E,Moorho Doenges,M.E,Moorhouse Doenges,M.E,Moorhouse Doenges,M.E,Moorhouse Doenges,M.E,Moorhouse Doenges,M.E,Moorhouse

M.F.,&Murr,A.C.(2010) use M.F.,&Murr,A.C. M.F.,&Murr,A.C.(2010) M.F.,&Murr,A.C.(2010) M.F.,&Murr,A.C.(2010) Nurses Pocket M.F.,&Murr,A.C. M.F.,&Murr,A.C.(2010)
Nurses Pocket Guide.12th (2010) Nurses Pocket Nurses Pocket Guide.12th Nurses Pocket Guide.12th Guide.12th Ed.FA:Davis Company: (2010) Nurses Pocket Nurses Pocket Guide.12th
Ed.FA:Davis Company: Guide.12th Ed.FA:Davis Company: Ed.FA:Davis Company: Pennsylvania Guide.12th Ed.FA:Davis Company:
Pennsylvania Ed.FA:Davis Pennsylvania Pennsylvania Ed.FA:Davis Pennsylvania
Company: Company:
Pennsylvania Pennsylvania

\
\